Recent Updates
Recently added Catalysts
NSPR

InspireMD to Report First Quarter 2019 Financial Results and Provide Business Update on Tuesday, May 14

Key Takeaway: TEL AVIV, Israel, May 07, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced today that it will host a conference call a

Full Press Release Details

TEL AVIV, Israel, May 07, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced today that it will host a conference call and webcast on Tuesday, May 14, 2019, to discuss financial results for the first quarter ended March 31, 2019, and provide a corporate update.
Conference Call & Webcast:
Tuesday, May 14th @ 8am Eastern Time
Within the US: 877-451-6152
Outside the US: 201-389-0879
Conference ID: 13689927
Webcast: http://public.viavid.com/index.php?id=134146
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for treatment of carotid artery disease by providing outstanding acute results and durable stroke free long-term outcomes.
InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.
Chief Financial Officer
LifeSci Advisors, LLC
Last updated: May 7, 2019